Common arthritis drugs reduce systemic Sjögren's disease activity in 24 weeks

06 Jun 2026, 19:40 · Medical Xpress

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process
Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

ESSDAI scores over 24 weeks of treatment with leflunomide–hydroxychloroquine or placebo: (A) Mean ESSDAI corrected for baseline, indicating the treatment effect of leflunomide–hydroxychloroquine versus placebo after 8 weeks, 16 weeks, and 24 weeks. Error bars indicate SEM. (B) Within-treatment paired ESSDAI differences between baseline and 24 weeks, with each line representing one patient. p values indicate the difference compared with baseline. Credit: Lancet Rheumatology

A combination of two widely available anti-rheumatic drugs offers the first effective and affordable treatment for patients with Sjögren's disease with systemic disease activity, according to new results from a clinical trial coordinated by UMC Utrecht. The study showed that treatment with leflunomide and hydroxychloroquine reduced disease activity in patients with moderate-to-severe disease while maintaining a favorable safety profile.

Sjögren's disease is a chronic autoimmune disease characterized by lymphocytic infiltration and functional impairment of exocrine glands. It affects approximately 0.5% of the population, mainly women. Patients experience severe dryness of the eyes and mouth, which is treated with artificial tears and saliva substitutes. In addition to these local symptoms, patients may develop systemic disease, with involvement of other organs, including the skin, lungs and kidneys. Furthermore, patients are at increased risk of developing non-Hodgkin lymphoma. Currently, a treatment to suppress systemic disease activity is lacking.

Clear treatment effect without background immunosuppressive therapy

In the RepurpSS-II trial (which was financed by ZonMw and ReumaNederland and coordinated by UMC Utrecht), 46 patients from 12 Dutch clinical centers were randomly assigned to receive either a placebo or daily oral treatment with leflunomide and hydroxychloroquine. Patients treated with the drug combination experienced a significantly greater reduction in disease activity, measured with the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), compared with placebo. The average difference between groups was more than four points (-4.135, 95% CI, -6.558 to -1.709, p=0.0012) after 24 weeks of treatment. This is a clinically meaningful improvement that closely mirrors the positive findings from the earlier RepurpSS-I proof-of-concept study.

In addition, using newer assessment methods for Sjögren's syndrome research, the STAR and CRESS scores, which include objective dryness and patient-reported outcomes alongside disease activity, the researchers also observed that more patients on active treatment responded positively. No clear significant improvement was found in secondary endpoints such as dryness, fatigue and pain.

Researchers say the results are particularly important because the study was conducted without background immunomodulatory therapy, allowing the effect of the drug combination to be assessed more accurately. According to the investigators, this makes RepurpSS-II the first trial to show positive results of conventional disease-modifying anti-rheumatic drugs (DMARDs) in Sjögren's disease, replicating the RepurpSS-I data. The treatment was generally well tolerated. Gastrointestinal complaints were the most common adverse events, occurring in both treatment groups. One serious adverse event, a myocardial infarction, occurred in the treatment arm but was probably unrelated to the study medication based on cardiac analysis.

"Our study confirms earlier proof-of-concept findings and represents the first successful conventional DMARD therapy in Sjögren's syndrome in a randomized, placebo-controlled setting without background immunosuppressive medication. As such, RepurpSS-II not only offers the prospect of a readily applicable treatment but also provides an important foundation for future mechanistic research," concludes immunologist and principal investigator of the study Joel van Roon, Ph.D. (Center for Translational Immunology and Department of Rheumatology & Clinical Immunology, UMC Utrecht).

Growing understanding of disease mechanisms

Beyond the clinical improvements, the findings also strengthen the growing understanding that Sjögren's disease is driven by multiple interacting immune pathways. Earlier mechanistic analyses from the RepurpSS program showed that the drug combination suppresses B-cell activity, interferon signaling and inflammatory chemokines associated with systemic disease activity.

The researchers believe these biological effects may have implications beyond symptom control alone. Persistent immune activation in Sjögren's disease has been linked to complications such as the development of non-Hodgkin lymphoma, suggesting that more effective immune suppression could also improve long-term outcomes.

Affordable and globally accessible treatment option

The authors note that further studies are needed to determine whether the treatment is equally effective in patients with lower systemic disease activity but high symptom burden, a group that represents a large proportion of Sjögren's patients. In addition, long-term tolerability will also require further evaluation.

Still, the investigators say that drug repurposing (in this case, combination therapy with leflunomide and hydroxychloroquine in Sjögren's disease) stands out because both drugs are already widely available, affordable and orally administered, advantages that could make the treatment accessible worldwide, including in lower-resource health care settings.

Publication details

Wing-Yi Wong et al, Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial, The Lancet Rheumatology (2026). DOI: 10.1016/s2665-9913(26)00075-5

Journal information: The Lancet Rheumatology

Key medical concepts

Sjogren's Syndrome

Clinical categories

RheumatologyAllergy and immunology Provided by University Medical Center Utrecht Who's behind this story?

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Common arthritis drugs reduce systemic Sjögren's disease activity in 24 weeks (2026, June 6) retrieved 6 June 2026 from https://medicalxpress.com/news/2026-06-common-arthritis-drugs-sjgren-disease.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.